TrialGynecologic oncology2023

Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).

Leslie M Randall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.